Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC

Area of Science:

• Oncology
• Translational Medicine
• Cancer Research

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved advanced EGFR-mutant non-small cell lung cancer (NSCLC) outcomes.
• Durable disease control is limited by residual disease, intratumoral heterogeneity, and resistance.
• Local consolidative therapy (LCT) targets residual tumor sites after systemic therapy.

Purpose of the Study:

• To review biological, translational, and clinical evidence for integrating LCT in advanced EGFR-mutant NSCLC.
• To explore mechanisms driving treatment failure and the rationale for eradicating residual lesions.
• To assess LCT's impact on survival and toxicity.

Main Methods:

• Literature search of PubMed (January 2000 - December 2025).
• Synthesis of mechanistic studies on treatment failure drivers.
• Analysis of randomized trials and real-world cohorts evaluating LCT.

Main Results:

• LCT is associated with improved progression-free survival and overall survival in selected patients.
• LCT demonstrates acceptable toxicity profiles.
• Mechanistic studies identify persister cells, resistant clones, and tumor microenvironments as key failure drivers.

Conclusions:

• LCT is a promising strategy to prolong disease control in advanced EGFR-mutant NSCLC.
• Advances in biomarkers may guide LCT as a precision strategy.
• LCT integration with systemic therapy can modify the natural history of advanced NSCLC.